Preparing stock dashboard...
Preparing stock dashboard...
6919.TW - Taiwan - Healthcare - Biotechnology
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.
Data updated June 18, 2026
| Metric | Value ('000,000) |
|---|
Latest period compared with the previous period and the matching prior-year period.
Loading financial changes...
Scores this stock using the same metrics model as the compare page.
| Metric | Value | Score |
|---|
Calculated locally from stored daily price and volume history.
Loading technical analysis...
Mouse wheel or pinch to zoom. Drag chart to pan. Double-click to reset zoom.